Xvivo Perfusion AB (CHIX:XVIVOS) Beginning Cash Position: kr308.1 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:XVIVOS Xvivo Perfusion AB CHIX:XVIVOS
87 GF Score
Price kr302.60
GF Value kr503.95
! 2 Warning Signs
View Full Analysis

What is Xvivo Perfusion AB Beginning Cash Position?

Xvivo Perfusion AB CHIX:XVIVOS 87 Beginning Cash Position is kr308.1 Mil as of Jun. 2026. GuruFocus rates CHIX:XVIVOS with a GF Score™ of 87/100 and a GF Value™ of kr503.95. The stock has 2 warning signs investors should review.

Xvivo Perfusion AB's Beginning Cash Position for the quarter that ended in Jun. 2026 was kr308.1 Mil.

Xvivo Perfusion AB's quarterly Beginning Cash Position increased from Dec. 2025 (kr279.9 Mil) to Mar. 2026 (kr292.1 Mil) and increased from Mar. 2026 (kr292.1 Mil) to Jun. 2026 (kr308.1 Mil).

Xvivo Perfusion AB's annual Beginning Cash Position increased from Dec. 2023 (kr246.5 Mil) to Dec. 2024 (kr546.1 Mil) but then declined from Dec. 2024 (kr546.1 Mil) to Dec. 2025 (kr415.5 Mil).

Xvivo Perfusion AB Beginning Cash Position Related Terms

Xvivo Perfusion AB Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Xvivo Perfusion AB's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xvivo Perfusion AB Beginning Cash Position Chart

Xvivo Perfusion AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 354.24 398.70 246.55 546.09 415.52

Xvivo Perfusion AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 315.87 323.00 279.94 292.09 308.14
CHIX:XVIVOS
87GF Score
Xvivo Perfusion AB CHIX:XVIVOS
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xvivo Perfusion AB Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of kr308.1 Mil mean?
Xvivo Perfusion AB (CHIX:XVIVOS) has a Beginning Cash Position of kr308.1 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Xvivo Perfusion AB and its competitors.
Is Xvivo Perfusion AB's Beginning Cash Position too high?
Xvivo Perfusion AB's current Beginning Cash Position is kr308.1 Mil. Overall, Xvivo Perfusion AB has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Beginning Cash Position compare to ABT and SYK?
Xvivo Perfusion AB's Beginning Cash Position of kr308.1 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Devices & Instruments company?
A good Beginning Cash Position depends on the Medical Devices & Instruments industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Xvivo Perfusion AB and its competitors. Xvivo Perfusion AB's current Beginning Cash Position is kr308.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Xvivo Perfusion AB (CHIX:XVIVOS) has a current Beginning Cash Position of kr308.1 Mil. The stock's GF Value™ is kr503.95, compared to a current price of kr302.60 — trading 40% below its estimated fair value. The current Beginning Cash Position is kr308.1 Mil. Xvivo Perfusion AB's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Xvivo Perfusion AB (CHIX:XVIVOS), the current Beginning Cash Position is kr308.1 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xvivo Perfusion AB (CHIX:XVIVOS) Overvalued in 2026?

Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued. The current stock price of kr302.60 is trading 40% below its estimated GF Value™ of kr503.95.

Key valuation signals for CHIX:XVIVOS:

  • Beginning Cash Position: kr308.1 Mil
  • GF Value™: kr503.95 vs. price of kr302.60 (40% below fair value)
  • GF Score™: 87/100 with 2 warning signs

No single metric tells the full story. See the CHIX:XVIVOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xvivo Perfusion AB Business Description

Address Gemenskapens gata 9, Molndal, SWE, SE-431 53
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
87GF Score

Get the complete analysis for CHIX:XVIVOS

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr302.60
Price
kr503.95
GF Value